Relay Therapeutics, Inc. (RLAY)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$18.03+3.38%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · RLAY
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Revenues | |||||||
| Revenues | — | 15.4 | 10.0 | 25.5 | 1.4 | 30.3 | 82.7 |
| Total Revenues | — | 15.4 | 10.0 | 25.5 | 1.4 | 30.3 | 82.7 |
| Operating Expenses & Income | |||||||
| R&D Expenses | — | — | — | — | — | — | 99.9 |
| Operating Income | (320.3) | (302.7) | (372.5) | (373.0) | (299.3) | (364.7) | (55.8) |
| Earnings from Continuing Operations | |||||||
| Income Tax Expense | — | — | — | — | — | — | 0.0 |
| Net Income | |||||||
| Net Income | (293.6) | (276.5) | (337.7) | (342.0) | (290.5) | (363.9) | (52.4) |
| Per Share | |||||||
| Basic EPS | (1.34) | (1.61) | (2.36) | (2.79) | (2.59) | — | (5.40) |
| Diluted EPS | — | (1.61) | (2.36) | (2.79) | (2.59) | — | (5.40) |
| Basic Weighted Avg Shares | 219.2 | 171.6 | 142.9 | 122.6 | 112.2 | — | 42.6 |
| Diluted Weighted Avg Shares | — | — | — | — | 112.2 | — | 42.6 |
| Supplemental | |||||||
| EBIT | (320.3) | (302.7) | (372.5) | (373.0) | (299.3) | (364.7) | (55.8) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.